FDA
-
-
-
-
-
-
-
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
H.C. Wainwright Downgrades IO Biotech (IOBT) to Neutral
-
-
-
-
-
-
-
IO Biotech (IOBT) PT Lowered to $4 at Morgan Stanley
-
-
-
-
-
-
-
IO Biotech (IOBT) Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112
-
-
-
-
-
-
-
IO Biotech (IOBT) Announces New Clinical Collaboration with Merck (MRK) to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA in Phase 2, Multi-cohort Trial in Patients with Re
-
-
-
-
-
-
-
IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial
-
-
-
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

